Description

SUMMARY Rationale: Pseudoxanthoma elasticum is a monogenic disease caused by mutations in the ABCC6 gene. These mutations result in reduced levels of inorganic pyrophosphate, a strong inhibitor of ectopic calcification. This loss of inorganic pyrophosphate leads to a typical pattern of progressive degradation and calcification of elastin fibers in the skin, the medial layer of small- and medium sized arteries and the Bruch's membrane of the retina. This results clinically in skin disorders (pseudoxanthoma's), peripheral arterial disease, gastric bleeding and stroke. The progressive calcification of the Bruch's membrane in the retina results in peau d' orange, angioid streaks, choroidal neovascularizations (CNV's) and macular atrophy. Due to this eye pathology, PXE results in visual impairment and legal blindness at a young age.

The bisphosphonate etidronate is a molecular homologue of pyrophosphate, which therefore has the potential to substitute the loss of pyrophosphate that is seen in PXE. It has been on the market for over 40 years and has a well-established safety profile. Based upon positive results from animal studies, studies in related genetic disorders, and trials in patients with renal disease, recently a double blind, randomized, placebo-controlled clinical trial (RCT) in PXE patients was conducted. This Treatment of Ectopic Mineralization in PXE (TEMP)-trial (protocol ID: NL47602.041.15) showed that one year of treatment with etidronate was safe, and reduced calcifications of the leg arteries and of other vascular beds compared to placebo in PXE patients with arterial calcifications. As no other systemic treatment for PXE exists, this established etidronate as a very promising therapeutic option. The TEMP trial focused on reduction of complications in symptomatic patients with arterial calcifications (mean age 57). Since arterial calcification are so common in PXE patients, the vascular diseases associated with them are as well much more prevalent in the PXE population compared to the general population.

The aim of the TEMP-PREVENT is to include younger patients who developed no or only little vascular calcifications. The investigators suspect that the formation of calcium deposits can be halted in the intima for a large part, if not all together. If so, PXE patients would have the same vascular risk profiles as their peers.

Objective: Primary aim:

To investigate the effect of etidronate on arterial calcification, and therefore vascular health.

Secondary aims:

To investigate the effect of etidronate on ophthalmological measures (including calcifications in Bruch's membrane), dermatological measurements, laboratory measurements, vascular measurements, incidence of major adverse cardiovascular events (MACEs), safety measures, and quality of life.

Study design: Double blind, placebo controlled, randomized clinical trial

Study population: Patients with a confirmed diagnosis of pseudoxanthoma elasticum from 18 - 50 years old.

Intervention: One group receives daily a dosis of 20mg/kg of etidronate in a cyclical regimen of 2 weeks on and 10 weeks off, for a total of 24 months. The other group receives a matching placebo with the same cyclical regimen and duration.

Main study endpoints: Primary endpoint:

The mean difference in the arterial calcification scores in the legs and the carotid syphon measured on low-dose CT scan after 24 months of treatment compared to baseline between etidronate and placebo.

Secondary endpoints:

Differences in Bruch's membrane reflectivity on high-definition spectral domain optical coherence tomography (HD-OCT); OCT-angiography; ophthalmological measures (visual acuity, fundus photography and autofluorescence), dermatological measurements (elastin degradation and calcification), measurement of pyrophosphate and desmosine, vascular measurements (calcification on CT, carotid intima thickness (cIMT), pulse wave velocity (PWV), ankle brachial index (ABI), WELCH questionnaire and the six-minute walking test), intracranial pulsatility and vascular anatomy on MRI, incidence of MACEs, quality of life (EQ-5D), and safety measures (calcium, phosphate, number of anti-VEGF injections), after 24 months of treatment compared to baseline between etidronate and placebo.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Each patient will visit the University Medical Center Utrecht (UMCU) four times during the study (screening, M0, M12, M24). A low dose scan of the head and the legs (M0, M24) will be made, for which the effective dosage of radiation is approximately 1.42 mSv in for a person with a weight of 70kg. The total radiation dosage for the study is therefore, approximately, 2.84 mSv. Theoretically, this radiation dose could increase the risk of future cancer. For ophthalmological assessments (M0, M12, M24), standard ophthalmological examination in combination with an OCT scan, will be performed, which yield no additional harm apart from the mydriatic eye drops. Dermatological assessments will be carried out by a punch biopsy of the skin (M0, M24), and laboratory assessments by venepuncture (M0, M12, M24), which, besides the normal risk associated with these procedures (hematoma, tenderness and swelling, persistent bleeding, vasovagal response, infection, hypersensitivity for anaesthesia) yield no additional harm. Given the well-established safety profile of etidronate and our experience from the TEMP trial, the investigators deem the overall risk of this trial to be low. The aim of this trial is to investigate the preventive effects of etidronate in PXE patients early in the disease. Given that we currently treat patients with etidronate only when arterial calcifications have already manifested, there is a potential clinical benefit to be gained by participation in this trial. Given the inhibitory effect of etidronate on arterial calcifications, it is expected that the TEMP-PREVENT trial opens new treatment possibilities for younger PXE patients.

        In order to be eligible to participate in this study, a subject must meet all of the
        following criteria:
          -  1. Be between 18 years and 50 years.
          -  2. Have a definitive diagnosis of PXE according to the Plomp criteria, which confirm a
             diagnosis of PXE when at least two (or more) criteria not belonging to the same
             category (skin, eye, genetic) are met:
               1. Skin
                    1. Yellowish papules and/or plaques on the lateral side of the neck and/or
                       flexural areas of the body or
                    2. Increase of morphologically altered elastin with fragmentation, clumping and
                       calcification of elastic fibers in a skin biopsy taken.
               2. Eye
                    1. Peau d'orange of the retina or
                    2. One or more angioid streaks (AS), each at least as long as one disk
                       diameter. When in doubt, fluorescein or indocyanine green angiography of the
                       fundus is needed for confirmation.
               3. Genetics
                    1. A pathogenic mutation of both alleles of the ABCC6 gene or
                    2. A first-degree relative (parent, sibling or child) who meets independently
                       the diagnostic criteria for definitive PXE
          -  3. Fertile women must take adequate anticonception.
        Exclusion Criteria:
        A potential subject who meets any of the following criteria will be excluded from
        participation in this study:
          1. Patients that are unable or unwilling to sign for informed consent.
          2. Pregnant, lactating, or fertile women who might wish to become pregnant within three
             years.**
          3. Patients with an estimated glomerular filtration rate below 30 ml/min/1.73m2 according
             to the CKD-EPI equation.31
          4. Patients with a known abnormality of the oesophagus that would interfere with passage
             of the drug (e.g. oesophagus stenosis).
          5. Patients with chronic diarrhoea (> 1 month).
          6. Patients with known osteomalacia;
          7. Patients with hypocalcaemia (calcium <2.20 mmol/L corrected for albumin)*.
          8. Patients with a vitamin D deficiency (<35 nmol/L)*.
          9. Patients that used a bisphosphonate in the last 5 years.
         10. Patients with known sensitivity to etidronate.
         11. Any other medical or social condition that, at the discretion of the Principal
             Investigator, might put the subject at risk of harm during the study or might
             adversely affect the interpretation of the study data.
               -  After correction a patient is again suitable for participation, as long as
                  inclusion criteria are met (more information in paragraph 7.3.3).
                    -  Subjects that become pregnant during the trial will be excluded from further
                       participation.